Colin Richard Green

CoDa Therapeutics (NZ) Ltd. develops and markets biopharmaceutical products. The company was founded by David Becker, Colin Green, Bradford J, Duft, and Howard E. Greene and on December 9, 2003 and is headquartered in Auckland, New Zealand.

AWE Pty Ltd. engages in the development and explored of oil and gas properties. Its projects includes Ande Ande Lumut Oil, BassGas, Casin Gas, Tui Area Oil, Lengo Gas, Waitsia Gas, Onshore Perth, Onshore Taranaki, and North Carnavon Basin. The company was founded by Bruce John Phillips on March 17, 1997 and is headquartered in North Sydney, Australia.

OcuNexus Therapeutics, Inc. develops and commercializes therapeutic products for wound care and tissue repair. The firm offers Nexagon, an oligonucleotide that downregulates the gap junction in tissue repair. Its Nexagon also reduces lesion spread, swelling, inflammation, scarring, and time to wound closure in various tissue types, including the eye, skin, spinal cord, nerve, and brain. The company was founded in 2005 by David Lawrence Becker, Colin C. Green and Bradford J. Duft and is headquartered in San Diego, CA.

InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy.